{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:50:01Z","timestamp":1791352201374,"version":"4.3.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with locally advanced gastric cancer (LAGC) typically require neoadjuvant chemotherapy (NAC) to reduce tumor burden and improve surgical resectability. However, treatment responses to NAC vary substantially among individuals. This study investigated the potential value of baseline serum growth differentiation factor 15 (GDF15) for identifying patients at risk of poor treatment response and unfavorable survival outcomes among patients with LAGC receiving NAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively identified 318 eligible patients with LAGC who received NAC and enrolled 30 healthy controls. Serum GDF15 levels were measured by ELISA. In the unmatched cohort, the median baseline serum GDF15 concentration (2,147.3 pg\/mL), determined before PSM, was used as a fixed cutoff to define the GDF15-L and GDF15-H groups (n = 159 each). After 1:1 PSM, 256 patients (n = 128 per group) were included in the matched analyses. Comparative analyses included baseline characteristics, CT images, preoperative endoscopic biopsy specimens and postoperative pathological features. Survival outcomes (OS and DFS) were assessed via Kaplan-Meier analysis. Multivariate Cox regression identified prognostic factors, and a prognostic nomogram was constructed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>High GDF15 expression correlated with advanced age (P = 0.045), poor tumor differentiation (P = 0.040), and elevated serum CA72-4 (P = 0.028). The GDF15-L group demonstrated superior median OS (58.1 vs. 54.0 months, P = 0.031) and DFS (47.1 vs. 26.9 months, P = 0.002) compared to GDF15-H counterparts. Preoperative endoscopic biopsy demonstrated a positive correlation between tissue GDF15 expression and serum GDF15 levels, while post-NAC imaging indicated greater tumor regression in the GDF15-L group. The GDF15-L group exhibited a higher pathological complete response (pCR) rate in postoperative pathological features (P &amp;lt; 0.001) while the GDF15-H group exhibited increased positive lymph nodes (P = 0.018) and a higher incidence of newly detected distant metastasis during or after NAC (P = 0.024). Multivariate analysis identified high GDF15 expression (P = 0.021) and high CAP degree (P = 0.022) as independent risk factors for OS, with younger age being protective (P = 0.016). Based on these factors, a prognostic nomogram was constructed to predict 1-year, 3-year, and 5-year OS and DFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Low baseline serum GDF15 levels were associated with favorable radiological and pathological responses and prolonged survival in patients with LAGC receiving NAC. Baseline serum GDF15 may help identify patients at increased risk of poor response and unfavorable prognosis and may therefore serve as a potential biomarker for pretreatment risk stratification. However, because all patients received NAC, these findings do not establish that GDF15 predicts differential benefit from NAC, and prospective validation is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmolb.2026.1948454","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:32Z","timestamp":1791348752000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum GDF15 as a potential biomarker for treatment response and survival in patients with resectable locally advanced gastric cancer undergoing neoadjuvant chemotherapy"],"prefix":"10.3389","volume":"13","author":[{"given":"Can","family":"Cao","sequence":"first","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunda","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pancreatic and Gastric Surgery, National Cancer Center\/ National Clinical Research Center for Cancer\/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikang","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyun","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moxi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pancreatic and Gastric Surgery, National Cancer Center\/ National Clinical Research Center for Cancer\/ Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"531","DOI":"10.6004\/jnccn.2013.0070","article-title":"Gastric cancer, version 2.2013: featured updates to the NCCN guidelines","volume":"11","author":"Ajani","year":"2013","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","article-title":"Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial","volume":"393","author":"Al-Batran","year":"2019","journal-title":"Lancet"},{"key":"B3","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3322\/caac.21388","article-title":"The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more \u201cpersonalized\u201d approach to cancer staging","volume":"67","author":"Amin","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"B4","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1053\/j.gastro.2020.02.068","article-title":"Global burden of 5 major types of gastrointestinal cancer","volume":"159","author":"Arnold","year":"2020","journal-title":"Gastroenterology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"11514","DOI":"10.1073\/pnas.94.21.11514","article-title":"MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily","volume":"94","author":"Bootcov","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B7","volume-title":"Protocol for the Examination of Specimens from Patients with Carcinoma of the Stomach","author":"Burghart","year":"2021"},{"key":"B8","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s12951-022-01481-y","article-title":"A pump-free and high-throughput microfluidic chip for highly sensitive SERS assay of gastric cancer-related circulating tumor DNA via a cascade signal amplification strategy","volume":"20","author":"Cao","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1158\/2767-9764.CRC-24-0565","article-title":"First-in-human study to evaluate the safety and efficacy of anti-GDF15 antibody AZD8853 in patients with advanced\/metastatic solid tumors","volume":"5","author":"Carneiro","year":"2025","journal-title":"Cancer Res. Commun."},{"key":"B10","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/S1470-2045(18)30132-3","article-title":"Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial","volume":"19","author":"Cats","year":"2018","journal-title":"Lancet Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"101569","DOI":"10.1016\/j.arr.2022.101569","article-title":"GDF15, an emerging key player in human aging","volume":"75","author":"Conte","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"946","DOI":"10.5966\/sctm.2013-0055","article-title":"Concise review: growth differentiation factor 15 in pathology: a clinical role?","volume":"2","author":"Corre","year":"2013","journal-title":"Stem Cells Transl. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/1078-0432.ccr-23-1631","article-title":"A phase Ib first-in-patient study assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of ponsegromab in participants with cancer and cachexia","volume":"30","author":"Crawford","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1158\/2159-8290.CD-16-0241","article-title":"Cellular senescence promotes adverse effects of chemotherapy and cancer relapse","volume":"7","author":"Demaria","year":"2017","journal-title":"Cancer Discov."},{"key":"B16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"101737","DOI":"10.1016\/j.arr.2022.101737","article-title":"Frailty biomarkers under the perspective of geroscience: a narrative review","volume":"81","author":"Gon\u00e7alves","year":"2022","journal-title":"Ageing Res. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1056\/NEJMoa2409515","article-title":"Ponsegromab for the treatment of cancer Cachexia","volume":"391","author":"Groarke","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00432-024-06036-2","article-title":"Suppressing GDF15 enhances the chemotherapeutic effect of 5 FU on MSI-H CRC by regulating the ferroptosis pathway SLC7A11\/GSH\/GPX4","volume":"151","author":"Huang","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s10120-020-01136-7","article-title":"Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial","volume":"24","author":"Iwasaki","year":"2021","journal-title":"Gastric Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.20.02914","article-title":"PRODIGY: a phase III study of neoadjuvant docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 Versus surgery and adjuvant S-1 for resectable advanced gastric cancer","volume":"39","author":"Kang","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1200\/JCO.23.02167","article-title":"Neoadjuvant docetaxel, Oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: updated overall survival outcomes from phase III PRODIGY","volume":"42","author":"Kang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1046\/j.1365-2168.2000.01358.x","article-title":"Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer","volume":"87","author":"Maehara","year":"2000","journal-title":"Br. J. Surg."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s41586-024-08305-z","article-title":"Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours","volume":"637","author":"Melero","year":"2025","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1053\/j.gastro.2020.12.015","article-title":"Hepatic stellate cells in hepatocellular carcinoma promote tumor growth Via growth differentiation factor 15 production","volume":"160","author":"Myojin","year":"2021","journal-title":"Gastroenterology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.ctrv.2007.01.004","article-title":"Chemotherapy of advanced gastric cancer","volume":"33","author":"Rivera","year":"2007","journal-title":"Cancer Treat. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"822","DOI":"10.3390\/cancers12040822","article-title":"Therapy-induced senescence: an \u201cold\u201d friend becomes the enemy","volume":"12","author":"Saleh","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","article-title":"Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European organisation for research and treatment of cancer randomized trial 40954","volume":"28","author":"Schuhmacher","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e14006","DOI":"10.1111\/acel.14006","article-title":"Biomarkers of cellular senescence and risk of death in humans","volume":"22","author":"St Sauver","year":"2023","journal-title":"Aging Cell"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1002\/ehf2.14738","article-title":"Prognostic significance of growth differentiation factor-15 across age in chronic heart failure","volume":"11","author":"Teramoto","year":"2024","journal-title":"Esc. Heart Fail"},{"key":"B31","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/annonc\/mdr284","article-title":"The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO\/world congress on gastrointestinal cancer, Barcelona, 2010","volume":"22","author":"Van Cutsem","year":"2011","journal-title":"Ann. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12885-020-07764-7","article-title":"The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial","volume":"21","author":"Wang","year":"","journal-title":"BMC Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e002787","DOI":"10.1136\/jitc-2021-002787","article-title":"GDF15 induces immunosuppression via CD48 on regulatory T cells in hepatocellular carcinoma","volume":"9","author":"Wang","year":"","journal-title":"J. Immunother. Cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1111\/febs.16992","article-title":"Mitochondrial dysfunction decreases cisplatin sensitivity in gastric cancer cells through upregulation of integrated stress response and mitokine GDF15","volume":"291","author":"Wang","year":"2024","journal-title":"FEBS J."},{"key":"B35","doi-asserted-by":"publisher","first-page":"4544","DOI":"10.7150\/thno.40532","article-title":"Tumor circulome in the liquid biopsies for cancer diagnosis and prognosis","volume":"10","author":"Wu","year":"2020","journal-title":"Theranostics"},{"key":"B36","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1111\/jcmm.16360","article-title":"Serum macrophage inhibitory cytokine-1 as a clinical marker for non-small cell lung cancer","volume":"25","author":"Xu","year":"2021","journal-title":"J. Cell Mol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s13073-024-01286-8","article-title":"Genomic and transcriptomic analysis of breast cancer identifies novel signatures associated with response to neoadjuvant chemotherapy","volume":"16","author":"Yin","year":"2024","journal-title":"Genome Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s00262-020-02598-5","article-title":"Activated HIF1\u03b1 of tumor cells promotes chemoresistance development via recruiting GDF15-producing tumor-associated macrophages in gastric cancer","volume":"69","author":"Yu","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1158\/0008-5472.CAN-24-0086","article-title":"Fibroblasts in the aged pancreas drive pancreatic cancer progression","volume":"84","author":"Zabransky","year":"2024","journal-title":"Cancer Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12885-018-4246-4","article-title":"GDF15 predict platinum response during first-line chemotherapy and can act as a complementary diagnostic serum biomarker with CA125 in epithelial ovarian cancer","volume":"18","author":"Zhao","year":"2018","journal-title":"BMC Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"7116","DOI":"10.7150\/jca.49224","article-title":"Exosomes derived from 5-fluorouracil-resistant colon cancer cells are enriched in GDF15 and can promote angiogenesis","volume":"11","author":"Zheng","year":"2020","journal-title":"J. Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"102129","DOI":"10.1016\/j.tranon.2024.102129","article-title":"GDF15 and LCN2 for early detection and prognosis of pancreatic cancer","volume":"50","author":"Zhu","year":"2024","journal-title":"Transl. Oncol."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1948454\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:40Z","timestamp":1791348760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2026.1948454\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":42,"alternative-id":["10.3389\/fmolb.2026.1948454"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2026.1948454","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1948454"}}